Cardiovascular Magnetic Resonance Imaging study assessing myocardial ischemia in patients with end-stage renal disease and renal transplant - End Stage Renal Disease cohort

Study of myocardial ischemia post renal transplant as assessed by Cardiac MRI in patients with end-stage renal disease - End Stage Renal Disease cohort

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000785909

Enrollment

Registered

2011-07-27

Start date

2011-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This project is designed to assess myocardial ischemia in various populations of patients with renal disease. These cohorts of patients have significant cardiovascular morbidity and mortality. It is believed that apart from epicardial coronary disease, they also have microvascular or small vessel ischemia. Dialysis is thought to be a major contributor in acceleration of their cardiovascular disease, however even after renal transplantation, there cardiovascular morbidity and mortality does not mirror the general population. We are going to assess myocardial ischemia using cardiac MRI and blood oxygen level dependent imaging. This uses intrinsic contrast of deoxy-hemoglobin to assess ischemia. We are going to assess it in patients on dialysis regardless of their cardiovascular symptoms as this group of patients have significant disease despite lack of traditional cardiac symptoms. We are also going to look at patients being evaluated for renal transplant. In this population, we can directly compare this relatively new technique with traditional method of ischemia assessment. We believe this technique will provided added information to already existing imaging modalities as it looks at oxygenation of the myocardium, which precedes development of ischemia. Our third cohort, evaluates patients after their renal transplant, examining markers that may predict cardiovascular morbidity and mortality in this group. This trial is the end stage renal disease cohort and is linked to ACTRN12611000783921 and ACTRN12611000786998

Interventions

Framingham's risk score at baseline (race, age, smoking history, family history of cardiac disease, cardiac risk factors) Blood tests at baseline - biochemical markers (hsCRP); markers of fibrosis (MMP); troponin T, BNP and homocysteine levels. Cardiac MRI at baseline - cine images; Blood oxygen level dependent MRI (BOLD) rest and stress using adenosine 140mcg/kg/min for 3-6 minutes Clinic visit at 12 months for repeat bloods. Phone follow up at 24 months

Study design

Allocation

Non-randomised trial

Primary purpose

Diagnosis

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with end-stage renal disease on haemodialysis or peritoneal dialysis and or GFR 30-60ml/min

Exclusion criteria

Known history of coronary artery disease, inability to give informed consent, extreme claustrophobia, implantable cardiac devices and other contra-indications to MRI, asthma or other reversible bronchospasm, patients on theophylline, inability to lie flat for 1 hour

Outcome results